Community-acquired and nosocomial infections caused by multidrug-resistant Gram-positive pathogens continue to increase in prevalence and have become a serious problem in many parts of the world. BAL9141 is a member of the class of parenteral pyrrolidinone-3-ylidenemethyl cephalosporins, and has a broad spectrum of activity. In the current study, BAL9141 was tested against a large number (n = 2263) of recent isolates from various international surveillance programmes including 1097 Gram-positive strains. Susceptibility to (S) and activity of (mg/L) to BAL9141, based on proposed breakpoints ( . All S. pneumoniae were inhibited by BAL9141 at ≤1 mg/L compared with CRO (90% S) and levofloxacin (LVX; 98% S). Susceptibility rates for viridans group streptococci to BAL9141 (>98%) were also higher than to CRO (86%) and LVX (96%). BAL9141 demonstrated excellent activity against most species of wild-type enteric bacilli, with ≥95% of isolates being susceptible; however, only modest activity was observed for BAL9141 against non-fermentative Gram-negative species and ESBL-producing Escherichia coli or Klebsiella pneumoniae. BAL9141 demonstrated excellent activity against many tested pathogens displaying various resistance phenotypes, and should be particularly valuable in the treatment of MRSA as well as for drug-resistant streptococci, while maintaining a spectrum resembling a 'third-generation' cephalosporin against other clinically important species.
Introduction
The problem of antimicrobial resistance among Gram-positive cocci has become critical to effective therapy of these organisms in many parts of the world. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Various types of resistance continue to increase, whereas others, such as penicillin resistance in Streptococcus pneumoniae 7, 8 or glycopeptide resistance among enterococci, 2, 9, 12 have stabilized at a worrisome elevated level. A number of factors have contributed to the emerging resistances, principally antimicrobial usage patterns (local, regional, national) and the quality of the infection control or public health infra-structures. 6 Even under better controls of formulary practice and hospital hygiene, the incidence of methicillin-resistant (MR) staphylococci in North American and European medical centres appears to be on the rise, as documented by the SENTRY Antimicrobial Surveillance Program. In the SENTRY Program, the MR Staphylococcus aureus (MRSA) rates between 1997 and 2000 increased in Europe (23-34%), North America (26-36%) and in the Asia-Pacific region (49-54%). Methicillin resistance among S. aureus or coagulase-negative staphylococci (CoNS) has been associated with high rates of co-resistance to fluoroquinolones such as ciprofloxacin and levofloxacin. 2, 12 Therefore, continued use of broad-spectrum β-lactams (third-or fourth-generation cephalosporins, some penicillin/β-lactamase inhibitor combinations, carbapenems) and fluoroquinolones is likely to foster an environment conducive to increased occurrence of MR staphylococci as infecting pathogens or colonizing microflora. An attempt to develop drugs in both of these antimicrobial classes with significant activity versus MR staphylococci could facilitate a reduction in this clinical problem.
Recently marketed fluoroquinolones (gatifloxacin, moxifloxacin, trovafloxacin) have possessed enhanced activity and spectra against MR staphylococci, although the proportion of these isolates inhibited still falls below 90%. 13 In contrast, novel parenteral cephalosporins have not been widely studied or developed in recent years. 14, 15 Among the recently described cephalosporins, the most studied has been RWJ-54428 (formerly MC-02,479). 16, 17 This parenteral agent reportedly has MIC 50 and MIC 90 values for MRSA of 1 and 2 mg/L, respectively, with the highest observed MIC being only 4 mg/L. 10 Similar MIC results for MRSA have been reported for BMS-247243 (MIC 90 4 mg/L), S-3578 (MIC 90 4 mg/L) and SM-197436 (MIC 90 2 mg/L), all parenteral cephalosporin derivatives. [18] [19] [20] BAL9141 (formerly Ro63-9141) is a new member of the pyrrolidinone-3-ylidenemethyl cephems that has documented activity against MR staphylococci (MIC 90 2-4 mg/L), Enterococcus faecalis (MIC 90 4 mg/L) and penicillin-resistant pneumococci (MIC 90 2 mg/L), while preserving the anti-Gram-negative activity of third-or fourth-generation cephalosporins. 21, 22 The mode of action of BAL9141 against staphylococci with altered PBP2a is a very high PBP enzyme affinity coupled with resistance to β-lactamases and a more stable acyl-enzyme complex. 21 Reports by the manufacturer of animal models of septicaemia, subcutaneous abscess and endocarditis showed that modest doses (10 mg/kg intraperitoneally) of BAL9141 effectively treated MR and vancomycin-intermediate S. aureus (VISA). 23 Andes & Craig 24 reported that BAL9141 exhibited in vivo cidal activity, with a moderate post-antibiotic effect (PAE; 3.8-4.8 h) against MRSA, and that T > MIC was the pharmacokinetic/pharmacodynamic (PK/PD) parameter best predicting in vitro efficacy.
This investigation was designed to confirm and extend the earlier presentations by the manufacturer about the potency and spectrum of BAL9141. A worldwide sample of organisms was selected from recent resistance surveillance trials, and tests were of reference quality 25-27 against over 2200 isolates.
Organism subsets were chosen to include major Grampositive and -negative species, community-acquired respiratory pathogens, problematic endemic species causing meningitis or sexually transmitted disease, and difficult-totreat anaerobic pathogens. Each category included isolates with resistance to different classes of drugs to challenge the spectrum of BAL9141 compared with numerous other antimicrobials. 28
Materials and methods

Antimicrobials tested
The BAL9141 reagent grade compound was provided by Hoffmann-LaRoche AG and Basilea Pharmaceutica AG (Basle, Switzerland). Comparator agents were purchased from Sigma Chemical Co. (St Louis, MO, USA) or obtained from their respective manufacturers in the USA. A total of up to 13 comparators were evaluated depending upon the species tested. These compounds included β-lactams [penicillins, cephalosporins, penicillin/β-lactamase inhibitor combinations, a monobactam (aztreonam) and carbapenems], fluoroquinolones, aminoglycosides, trimethoprim/sulfamethoxazole and Gram-positive focused agents (macrolide-lincosamidestreptogramins, glycopeptides, oxazolidinones).
Organisms tested
The test strains (more than 2200) used in this study were derived from worldwide surveillance trials between 1997 and 2000. Larger numbers of resistant phenotypes were selected among the Gram-positive cocci to challenge the BAL9141 spectrum. (17) and Burkholderia cepacia (eight). Neisseria meningitidis (24), Neisseria gonorrhoeae (32), Bacteroides fragilis group (44) and Clostridium spp. (10) were also sampled. All strains were identified by at least two laboratories to species level. Strains were stored at -70°C or below until processed.
Susceptibility testing methods
All tests were carried out using the reference broth microdilution or agar dilution (Neisseria spp. and anaerobes) methods described by the NCCLS. 25, 26 Cation-adjusted Mueller-Hinton broth was modified for streptococci by supplementation with 5% lysed horse blood, whereas for H. influenzae the Haemophilus Test Medium (HTM) formulation was used. Brucella blood agar and supplemented GC agar (IsoVitaleX) were used for anaerobes and pathogenic Neisseria spp., respectively. Isolates with ESBL phenotypes for E. coli and K. pneumoniae were selected using the NCCLS criteria 26 and all enzymes were shown to be inhibited by clavulanic acid (≥8-fold reduction in the MIC). All tests followed NCCLS technical details 25 Interpretative criteria were those published in NCCLS M100-S12 27 and a conservative ≤4 mg/L was used for BAL9141 (comparisons only) when testing enterococci, Enterobacteriaceae, non-enteric Gram-negative bacilli and staphylococci, whereas BAL9141 breakpoints for Haemophilus spp. and streptococci were set at ≤2 and ≤1 mg/L, respectively (those levels currently utilized for cefepime, cefotaxime and ceftriaxone). 27 Particular attention was made to accurately characterize staphylococci for oxacillin (methicillin) resistance 29, 30 and to detect strains having reduced susceptibilities to glycopeptides. 3, 4 BAL9141 MIC values were ≤2 mg/L for S. aureus, with MIC 50 and MIC 90 values of 0.5 and 0.5 mg/L and 1 and 2 mg/L for oxacillin-susceptible (OS) and MR (also oxacillin-resistant) strains, respectively. All antimicrobials except penicillin were effective in vitro against OS S. aureus, with susceptibility ranging from 78.0% (erythromycin) to 100.0% (eight agents). However, for the 96 strains of MRSA, only BAL9141, vancomycin (MIC 90 2 mg/L; 100.0% susceptible) and linezolid (MIC 90 2 mg/L; 100.0% susceptible) remained highly effective. Methicillin-sensitive strains were slightly more susceptible (two-to four-fold) to BAL9141 than MRSA strains. CoNS strains were slightly more susceptible to BAL9141 than S. aureus isolates, although the highest BAL9141 MIC was identified for an MR-CoNS isolate. OS-CoNS strains were more susceptible to BAL9141 when compared with MR-CoNS isolates. All antimicrobials tested had a ≥92.3% susceptibility rate versus OS-CoNS, except penicillin (42.3% susceptible), erythromycin (73.1%) and trimethoprim/ sulfamethoxazole (73.1%). Only four tested antimicrobials inhibited MR-CoNS strains at a rate >90%: BAL9141 (100.0% inhibited at ≤4 mg/L), linezolid (100.0% susceptible), vancomycin (98.9% susceptible) and quinupristin/dalfopristin (94.4% susceptible). All CoNS strains selected to challenge BAL9141 against defined glycopeptide-intermediate (one strain), macrolide and clindamycin-resistant (56 strains), streptogramin-resistant (five strains) and fluoroquinoloneresistant (59 strains) populations were inhibited by ≤4 mg/L BAL9141. Table 1 also lists BAL9141 activity tested against 132 strains of enterococci. The BAL9141 activity versus E. faecalis paralleled that of ampicillin (93.5% susceptible), penicillin (90.3%) and co-amoxiclav (93.5%). The BAL9141 MIC 90 (4 mg/L) was identical to that of ampicillin and co-amoxiclav. Ciprofloxacin and levofloxacin were active against 40.3-52.8% of strains at MICs at or below their NCCLS breakpoints. Table 2 shows the potency of BAL9141 and 12 comparison agents tested against various streptococcal species groups listed according to their susceptibilities to penicillin. BAL9141 activity was at least four-fold greater than that of ceftriaxone towards strains with reduced susceptibilities to penicillin (MIC ≥ 0.12 mg/L). Among the four clinically available β-lactams tested, ceftriaxone and amoxicillin ± clavulanate demonstrated nearly complete coverage of pneumococci with penicillin MICs of ≤1 mg/L. However, only 52.6-58.8% of penicillin-resistant strains were inhibited by these agents. Generally, the fluoroquinolones tended to be more active than the β-lactams.
Results
BAL9141 activity against staphylococci
BAL9141 activity against enterococci
BAL9141 activity against streptococci
Activity of the β-lactams (including BAL9141), macrolides, clindamycin and trimethoprim/sulfamethoxazole decreased as the penicillin MIC increased. The potency of BAL9141 was equal to that of the fluoroquinolones against penicillinresistant S. pneumoniae on a weight-weight basis (Table 2) .
Viridans group streptococci were generally more resistant to the β-lactams, macrolides, clindamycin, fluoroquinolones and trimethoprim/sulfamethoxazole than the S. pneumoniae isolates. BAL9141 MIC 90 results varied from 0.06 mg/L for penicillin-susceptible strains to 0.25 and 1 mg/L for penicillinintermediate and -resistant strains, respectively. At current NCCLS breakpoints for susceptibility, ceftriaxone and coamoxiclav were most potent among the β-lactams, but the glycopeptides (vancomycin, teicoplanin) and quinupristin/ dalfopristin had the highest level of susceptibility (≥90.0%). If the current breakpoint for ceftriaxone (susceptible at ≤1 mg/L) was applied to BAL9141, only one viridans group streptococcus strain would not have been judged BAL9141 susceptible (1.2%). β-Haemolytic streptococci were very susceptible to BAL9141 (MIC 90 ≤ 0.015 mg/L) and most other drugs tested. Only erythromycin had a susceptibility rate <98.0% (88.3%).
BAL9141 activity against H. influenzae and M. catarrhalis
H. influenzae strains were uniformly susceptible to BAL9141 (MIC 90 0.06 mg/L), as well as to ceftriaxone and cefepime ( M. catarrhalis isolates lacking β-lactamase production (11.2%) were significantly more susceptible (MIC 90 0.015 mg/L) to BAL9141 compared with their β-lactamasepositive counterparts (MIC 90 0.5 mg/L; data not shown). Only three isolates among 188 strains tested (1.6%) had a BAL9141 MIC of 1 mg/L (Table 3) . Overall, M. catarrhalis isolates were very susceptible to all β-lactams tested (≥95.2% susceptible) with the exception of penicillin.
BAL9141 activity against Enterobacteriaceae
BAL9141 exhibited good activity against Gram-negative enteric bacilli with susceptibility rates that ranged between 79.4% and 100% using a proposed breakpoint of ≤4 mg/L (Table 4 ). Significant BAL9141 potency was most notable for Citrobacter spp., E. coli, Enterobacter cloacae, Klebsiella spp., P. mirabilis, Salmonella spp. and Shigella spp., which collectively had MIC 90 values ranging from 0.03 to 0.5 mg/L. Against Citrobacter freundii the MIC 90 of BAL9141 (0.5 mg/L) was the same as noted for cefepime and imipenem, with susceptibility rates also similar for these compounds and the two fluoroquinolones tested (>94%). The remaining effective compounds in vitro showed a rank order of: gentamicin (94.1%) > piperacillin/tazobactam, aztreonam (85.3%) > ceftazidime, ceftriaxone (82.4%). The E. coli isolates were all susceptible to BAL9141, cefepime, and the carbapenems with very similar potencies (MIC 90 ≤ 0.12-0.25 mg/L). The extended-and broad-spectrum cephalosporins piperacillin/ tazobactam, gentamicin and aztreonam were slightly less active (95.3-97.7% susceptible). The two fluoroquinolones showed equivalent activities (86% susceptible), but a rate similar only to that of cefazolin. E. cloacae isolates were most susceptible to cefepime and the carbapenems (100%); however, the potency of BAL9141 (MIC 90 0.12 mg/L) was equal to or greater than these compounds, and shared an activity most similar to gentamicin and the fluoroquinolones (98.3% susceptible). Against K. pneumoniae, all test agents showed excellent activity, with BAL9141 activity most similar to that of cefoxitin and ciprofloxacin (96% susceptible). All compounds were active against K. oxytoca (except cefazolin; only 75% susceptible), P. mirabilis, Salmonella spp. (except quinolones; only 90.9% susceptible) and pounds having marginal or no activity. Among the indolepositive Proteae, P. vulgaris (one-third of the isolates in this group) was refractory to BAL9141 (MIC 50 /MIC 90 , % susceptible were 32/>32 mg/L, 36.4%). Regardless, the activity of BAL9141 (79.4%) towards these cited species remained higher than that of the comparator fluoroquinolones (76.9% susceptible), but lower than that of other 'broad-spectrum' cephalosporins, piperacillin/tazobactam, gentamicin, aztreonam and the carbapenems (88.5-100% susceptible). Table 5 provides in vitro susceptibility data on E. coli and K. pneumoniae exhibiting confirmed ESBL phenotypes. With the exception of the carbapenems, the potency of all agents tested was diminished compared with wild-type ESBL-negative strains (Table 4) . Indeed nearly all MIC 90 s exceeded the maximum test concentrations, except for the carbapenems, which retained complete activity against the ESBL-positive strains. Among the E. coli isolates, BAL9141 activity was most similar to that of ceftriaxone and aztreonam, which in turn were more active than tetracycline and trimethoprim/sulfamethoxazole.
BAL9141 activity against non-fermentative Gram-negative bacilli
BAL9141 demonstrated widely variable activity against the tested non-fermentative Gram-negative bacilli, as shown by Table 7 summarizes the BAL9141 activity compared with a limited number of antimicrobials tested by agar dilution methods against N. meningitidis, N. gonorrhoeae and 54 strains of anaerobic bacteria. BAL9141 proved to be two-to fourfold more active than cefotaxime against the pathogenic Neisseria. The highest MIC of BAL9141 was for the gonococcal strains at 0.06 mg/L (susceptible by criteria applied to either cefotaxime or ceftriaxone).
Activity of BAL9141 against Neisseria and anaerobes
The Clostridium spp. strains were generally BAL9141-susceptible with an MIC 90 of ≤0.25 mg/L, rates comparable to cefotaxime, but inferior to the comparison carbapenem. In contrast, B. fragilis group anaerobes were less susceptible to inhibition by BAL9141 (MIC 90 > 64 mg/L). However, BAL9141 seems to be slightly more active than cefotaxime versus these B. fragilis group isolates (Table 7) .
Discussion
Since the first reports of methicillin resistance in S. aureus nearly four decades ago, 31 pharmaceutical scientists have sought β-lactam molecules active against these strains. Numerous candidate agents have been studied, many with high affinities for the mecA gene product (PBP2a) responsible for the resistance. 32 Structurally diverse β-lactams have been developed to address this need, including carbapenems 14, 15, [32] [33] [34] and numerous cephalosporin derivat-ives, [14] [15] [16] [17] 21, 22 including BAL9141. In this report, we confirm the potency of BAL9141 against MR staphylococci, including multidrug-resistant strains and those organisms with elevated glycopeptide MICs. 3, 4 Specifically, BAL9141 was eight-fold more active than ceftriaxone against OS staphylococci and no MRSA had a BAL9141 MIC of >2 mg/L, validating the report by Hebeisen et al. 21 and showing activity similar to that of RWJ-54428. 16 Although highly promising against MR staphylococci, the BAL9141 activity versus penicillin-resistant S. pneumoniae Since all currently marketed β-lactams are considered clinically inactive against MR staphylococci, 25,27 the probability of adverse selection of resistant strains in the hospital environment using cephalosporins remains high. The concurrent co-resistance of these MR staphylococci to the most popularly used parenteral fluoroquinolones (ciprofloxacin, levofloxacin) contributes to an even greater risk of escalating rates of MRSA isolation. The clinical availability of a cephalosporin candidate (BAL9141) with MRSA activity presents the option of a therapeutic broad-spectrum cephalosporin coupled with environmental (patient or hospital) suppression of MR staphylococci. Indeed, in vivo animal model results 21 suggest that BAL9141 could be utilized as directed therapy of MRSA infections, including those possessing reduced susceptibility to vancomycin. Results of initial clinical trials as well as human pharmacokinetic results leading to the establishment of a reliable breakpoint for BAL9141 susceptibility are eagerly awaited. Early trials appear warranted to follow the effects of therapy on patient colonization by resistant Gram-positive pathogens and changes in normal flora. 
